<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843634</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 63137</org_study_id>
    <nct_id>NCT01843634</nct_id>
  </id_info>
  <brief_title>Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Preliminary Evidence of a Therapeutic Effect of ODSH (2-0, 3-0, Desulfated Heparin) in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label pilot study evaluating the safety and preliminary evidence of a&#xD;
      therapeutic effect of ODSH (2-0, 3-0 desulfated heparin) in conjunction with standard&#xD;
      induction and consolidation therapy for acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety by incidence of serious events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy by time to platelet recovery</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>ODSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODSH</intervention_name>
    <arm_group_label>ODSH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, previously untreated acute myeloid leukemia. Acute promyelocytic&#xD;
             leukemia is excluded.&#xD;
&#xD;
          -  No prior chemotherapy for acute myeloid leukemia; however, prior hydroxyurea to&#xD;
             control white blood cell count is allowed.&#xD;
&#xD;
          -  No prior chemotherapy or lenalinomide for treatment of myelodysplastic syndrome.&#xD;
&#xD;
          -  Age: 18-70.&#xD;
&#xD;
          -  ECOG Performance status 0-2&#xD;
&#xD;
          -  Cardiac ejection fraction â‰¥ 50% (echocardiography or MUGA [multigated acquisition])&#xD;
&#xD;
          -  Adequate hepatic and renal function (AST [aminotransferase], ALT [alanine&#xD;
             aminotransferase], bilirubin and creatinine &lt; 2.5 x upper normal limit).&#xD;
&#xD;
          -  Able to provide informed consent and have signed an approved consent form that&#xD;
             conforms to federal and institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia&#xD;
&#xD;
          -  Patients with acute megakaryoblastic leukemia&#xD;
&#xD;
          -  Patients with CNS (central nervous system) leukemia&#xD;
&#xD;
          -  Presence of significant active infection or uncontrolled bleeding&#xD;
&#xD;
          -  Any coexisting major illness or organ failure which contraindicates the dose-intensive&#xD;
             chemotherapy regimen prescribed by this protocol&#xD;
&#xD;
          -  Pre-existing liver disease that might impair ODSH clearance&#xD;
&#xD;
          -  History of other active malignant disease within 5 years, other than cured basal cell&#xD;
             carcinoma of the skin, cured in situ carcinoma of the cervix, or localized prostate&#xD;
             cancer that has received definitive therapy. Such prostate cancer patients who are&#xD;
             receiving hormonal therapy are eligible&#xD;
&#xD;
          -  Use of recreational drugs or history of drug addiction, within the prior 6 months&#xD;
&#xD;
          -  Known history of positive hepatitis B surface antigens or hepatitis C antibodies&#xD;
&#xD;
          -  Known history of positive test for HIV (Human immunodeficiency virus) antibodies&#xD;
&#xD;
          -  Psychiatric or neurologic conditions that could impair ability to give proper informed&#xD;
             consent&#xD;
&#xD;
          -  Presence of symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             symptomatic or poorly controlled cardiac arrhythmia&#xD;
&#xD;
          -  Presence of uncontrolled thrombotic or hemorrhagic disorder&#xD;
&#xD;
          -  A medical condition that requires the need to be on chronic anticoagulation&#xD;
&#xD;
          -  Presence of any other serious uncontrolled medical disorder&#xD;
&#xD;
          -  Treatment with any other investigational agent, or participation in another clinical&#xD;
             trial within 28 days prior to study entry&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  Patient with childbearing potential not using adequate contraception&#xD;
&#xD;
          -  Hemorrhage risk that requires maintenance of platelet counts at 50,000/uL or higher.&#xD;
&#xD;
          -  Any significant concurrent disease, illness, or psychiatric disorder that would&#xD;
             compromise patient safety or compliance, interfere with consent, study participation,&#xD;
             follow up, or interpretation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Shami, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

